Liladros

Drospirenone/Ethinylestradiol, the active ingredient in Liladros, is a combined oral contraceptive presented as a tablet for oral use. It effectively prevents pregnancy by inhibiting ovulation and altering cervical mucus in women of reproductive age.

GNH USA supplies Liladros as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product is authorized in the European Union and meets international quality standards, providing reliable access to this hormonal contraceptive for qualified prescribers. GNH USA also ensures consistent supply chains and regulatory compliance for global distribution.

Liladros, a combined oral contraceptive, is used to prevent pregnancy by suppressing ovulation and modifying cervical mucus.

- Pregnancy prevention: prevents conception when taken as directed. - Contraception: provides reliable birth control for women of reproductive age. - Menstrual cycle regulation: can help achieve more predictable menstrual bleeding patterns.

Liladros may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: occasional mild to moderate pain. - Weight gain: modest increase in body weight. - Mood changes: fluctuations in emotional state. - Spotting: irregular light bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Arterial thrombosis: clot formation in arteries, potentially causing stroke or heart attack. - Hypertension: elevated blood pressure. - Liver disorders: jaundice or hepatic dysfunction. - Gallbladder disease: gallstones or cholecystitis. - Severe allergic reaction: anaphylaxis or angioedema.

Before prescribing Liladros, clinicians should consider several safety factors.

- Assess cardiovascular risk: evaluate history of thromboembolic events before prescribing. - Screen for smoking status: avoid use in women over 35 who smoke. - Consider liver function: use cautiously in hepatic impairment. - Monitor blood pressure: combined estrogen‑progestin can raise blood pressure. - Avoid use during pregnancy: contraindicated (Category X). - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Liladros can interact with other medicines, requiring attention to potential changes in effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect and increase bleeding risk. - Certain antiretrovirals (e.g., efavirenz): may lower hormone levels and compromise contraception.

Moderate Interactions (Monitor Closely): - SSRIs: may increase risk of mood‑related side effects. - Antihypertensives: combined pill may reduce blood‑pressure‑lowering effect. - Herbal supplements (e.g., St. John’s wort): may decrease contraceptive effectiveness.